Company Overview and News

37
CANADA STOCKS - TSX dips 0.14 percent after U.S. Fed rate hike

2018-06-13 reuters
NEW YORK, June 13 (Reuters) - * The Toronto Stock Exchange’s S&P/TSX fell 23.16 points, or 0.14 percent, to 16,265.82. * The biggest weight to the TSX loss was Suncor Energy with a drag of 5.35 index points. In turn, energy weighed by 18.7 points on the index. * Leading the index were Aecon Group Inc, up 3.7 percent, NovaGold Resources Inc, up 3.7 percent, and Precision Drilling Corp , higher by 3.
IFSPF ACBFF IVN NG PDS CGC SU AEGXF IVPAF TWMJF ACB WEED BDRPF ARE PFSCF SU

0
China’s belt and road builder finds itself embroiled in a scandal in Malaysian coastal railway link

2018-06-12 scmp
China Communications Construction Company, one of the world’s largest engineering and construction companies by contract value, has found its biggest project in Malaysia embroiled in controversy ever since it agreed to build the 620-kilometer rail link spanning the east coast of the Southeast Asian country.
AEGXF 1800 ARE 0694

4
PRESS DIGEST-Canada - May 30

2018-05-30 reuters
May 30 (Reuters) - The following are the top stories from selected Canadian newspapers. Reuters has not verified these stories and does not vouch for their accuracy.
CPG AEGXF CP CP CPG ARE

0
Aecon shares plunge more than 15 per cent after Ottawa blocks sale to Chinese state-owned company

2018-05-25 thestar
This copy is for your personal non-commercial use only. To order presentation-ready copies of Toronto Star content for distribution to colleagues, clients or customers, or inquire about permissions/licensing, please go to: www.TorontoStarReprints.com
AEGXF ARE

0
Aecon withdraws from group bidding to build Gordie Howe bridge between Canada, U.S.

2018-05-04 thestar
This copy is for your personal non-commercial use only. To order presentation-ready copies of Toronto Star content for distribution to colleagues, clients or customers, or inquire about permissions/licensing, please go to: www.TorontoStarReprints.com
AEGXF ARE

0
Aecon Pulls Out of Gordie Howe Bridge Bidding Amid Chinese Takeover - Bloomberg

2018-05-04 bloomberg
Connecting decision makers to a dynamic network of information, people and ideas, Bloomberg quickly and accurately delivers business and financial information, news and insight around the world.
AEGXF 1800 ARE

54
PRESS DIGEST- Canada-April 11

2018-04-11 reuters
April 11 (Reuters) - The following are the top stories from selected Canadian newspapers. Reuters has not verified these stories and does not vouch for their accuracy.
AEGXF GOOGL ARE GOOG BBRY

0
Aecon extends deadline to complete sale to Chinese company as federal review continues

2018-03-28 cbc.ca
The deadline for Aecon Group Inc. to complete its sale to a Chinese state-owned business has been extended to July 13 as Ottawa continues its national security review of the $1.5-billion deal.
AEGXF ARE

157
PRESS DIGEST-Canada-March 28

2018-03-28 reuters
March 28 (Reuters) - The following are the top stories from selected Canadian newspapers. Reuters has not verified these stories and does not vouch for their accuracy.
AEGXF AAPL THI ARE

0
Aecon Trades at Widest Gap to CCCC Offer as Concerns Mount - Bloomberg

2018-03-21 bloomberg
Connecting decision makers to a dynamic network of information, people and ideas, Bloomberg quickly and accurately delivers business and financial information, news and insight around the world.
AEGXF 1800 ARE

0
BRIEF-Aecon Partnership Finalizes Contract For Site C Generating Station And Spillways Civil Works

2018-03-16 reuters
* AECON GROUP INC - CO IS MANAGING PARTNER OF CONSORTIUM AND HOLDS A 30 PER CENT SHARE OF PARTNERSHIP
AEGXF ARE

Related Articles

CASC: Cascadian Therapeutics Analysis and Research Report

7h - Asif

Overview Cascadian Therapeutics is a clinical-stage biopharmaceutical company focused on the development of therapeutic products for the treatment of cancer. The company's goal is to develop and commercialize novel targeted compounds that have the potential to improve the lives and outcomes of cancer patients. The company's lead clinical-stage product candidate is tucatinib, an oral, HER2-selective small molecule tyrosine kinase inhibitor. The company's pipeline also includes two preclinical-stage product candidates: CASC-578, a Chk1 kinase inhibitor, and CASC-674, an antibody program against an immuno-oncology target known as TIGIT. 2018 Merger Agreement On January 30, 2018, the company entered into an Agreement and Plan of Merger (the Merger Agreement) with Seattle Genetics, Inc., a Delaware corporation (Seattle Genetics), and Valley Acquisition Sub, Inc., a Delaware corporation and a wholly owned subsidiary of Seattle Genetics (Merger Sub). Pursuant to the Merger ...

BAC: Bank of America Corp. Analysis and Research Report

8h - Asif

Business Overview The Corporation is a Delaware corporation, a bank holding company (BHC) and a financial holding company. When used in this report, “the Corporation” may refer to Bank of America Corporation individually, Bank of America Corporation and its subsidiaries, or certain of Bank of America Corporation’s subsidiaries or affiliates. The company's principal executive offices are located in Charlotte, North Carolina. Through its banking and various nonbank subsidiaries throughout the U.S. and in international markets, the company provide a diversified range of banking and nonbank financial services and products through four business segments: Consumer Banking, Global Wealth & Investment Management (GWIM), Global Banking and Global Markets, with the remaining operations recorded in All Other. The company operate its banking activities primarily under the Bank of America, National Association (Bank of America, N.A. or BANA) charter. At March 31, 2018, the Corporation had a...

ARWR: Arrowhead Pharmaceuticals Analysis and Research Report

2018-06-18 - Asif

Business Arrowhead develops medicines that treat intractable diseases by silencing the genes that cause them. Using a broad portfolio of RNA chemistries and efficient modes of delivery, Arrowhead therapies trigger the RNA interference mechanism to induce rapid, deep and durable knockdown of target genes. RNA interference, or RNAi, is a mechanism present in living cells that inhibits the expression of a specific gene, thereby affecting the production of a specific protein. Deemed to be one of the most important recent discoveries in life science with the potential to transform medicine, the discoverers of RNAi were awarded a Nobel Prize in 2006 for their work. Arrowhead’s RNAi-based therapeutics leverage this natural pathway of gene silencing. In fiscal 2017, Arrowhead refocused its resources on therapeutics that exclusively utilize the company’s Targeted RNAi Molecule (TRiMTM) platform technology. Therapeutics built on the TRiMTM platform have demonstrated high levels of pha...

Silicon Investor Message Boards

This table lists all message boards related to TSX:ARE / Aecon Group Inc on message board site Silicon Investor.

Pennies Arent Dead Rare Earth Elements and Exotic Metals
A US National Health Care System? Margaret Sangeru0027s Eugenic Legacy of Death, Disease, Depravit
Where the GITu0027s are going Tableau Software
Check Point Software (CHKP) Survivalists, Disaster Preparedness and Living Off the Grid
Got A Great Recipe To Share???? CDN gold shares: Anaconda mining merging w/Maritime Resource